Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107717 · ClinicalTrials.gov registry record · Phase 4
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 318
- Enrollment target
NCT01107717 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 318 participants.
The verdict
NCT01107717, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 318 participants
- Enrollment target
Study Summary
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its complications. Multiple defects, e.g. impaired insulin secretion and impaired insulin action, contribute to the development of the disease. The aim of this study is to test the efficacy and durability of combination of drugs which correct the defects that lead to the development of diabetes on achieving adequate and durable control of blood sugar levels. Achieving adequate and durable control of blood sugar will prevent many of diabetes complications.
Interventions
- DRUG metformin\pioglitazone\exenatide
- DRUG metformin, glyburide and glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2009-01 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107717
The ClinicalTrials.gov registry entry for NCT01107717 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which metformin\pioglitazone\exenatide is the first listed.
NCT01107717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01107717 about?
NCT01107717 is a clinical study titled "Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM". Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its complications. Multiple defects, e.g. impaired insulin secretion and i...
What is the current status of trial NCT01107717?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 318 participants. The study started on 2009-01. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT01107717?
The interventions under investigation include: metformin\pioglitazone\exenatide (DRUG), metformin, glyburide and glargine (DRUG).
Who is sponsoring clinical trial NCT01107717?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.